Podcasts about colorado school

Circumcision is one of the most common procedures performed in newborns. For such a frequent procedure, it can stir up big conversations in the primary care office. How do you help families make informed decisions? What technique details really matter? What's the role of the pediatrician when something doesn't look quite right in the days that follow? In this episode, we're unpacking the real-world essentials of circumcision in primary care from evidence-based counseling to timing, pain control, and navigating those questionable moments. Kelly Harris, MD, and Brian Caldwell, MD, both specialize in urology at Children's Hospital Colorado. Dr. Harris is an assistant professor, and Dr. Caldwell is an associate professor at the University of Colorado School of Medicine Some highlights from this episode include: How common circumcision is in modern day  Why the decision to have one or not is very individualized to each family  How the pediatrician can support families in this decision-making process  Most common side effects  For more information on Children's Colorado, visit: childrenscolorado.org. 

This legislative session is the swan song for Colorado's outgoing governor, Jared Polis. He still has a lot on his "to do" list, but policy clashes within his own party could create some challenges. We explore that today with Purplish. Then, a researcher at the Colorado School of Mines has developed a new way to treat deep wounds, and that could just be the beginning for its use. Also, what Colorado's two largest cities are doing to send a message to ICE. Plus, we answer a Colorado Wonders question about the impact of moose on our state. 

Rory Johnston is a Toronto-based oil market researcher, the founder of Commodity Context, a lecturer at the University of Toronto's Munk School of Global Affairs and Public Policy, as well as a Fellow with both the Canadian Global Affairs Institute and the Payne Institute for Public Policy at the Colorado School of Mines. Prior to founding Commodity Context, Rory led commodity economics research at Scotiabank. In this podcast, we discuss:   Trump's Bullish Paradox   Importance of China's SPR Why OPEC+ Hiked Production The "Oil on Water" Overhang   Venezuela and Iran 2026 Outlook   US Shale's H2 Roll-over Long term demand outlook 

Pediatric neuropalliative medicine is an emerging area of subspecialty practice that emphasizes the human experience elements of serious neurologic illness. Child neurologists care daily for patients who can benefit from the communication strategies and management practices central to pediatric neuropalliative medicine, whether at the primary or subspecialty level. In this episode, Gordon Smith, MD, FAAN, speaks with Lauren Treat, MD, author of the article "Neuropalliative Medicine in Pediatric Neurology" in the Continuum® December 2025 Neuropalliative Care issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Treat is an associate professor in the divisions of child neurology and palliative medicine at the University of Colorado School of Medicine in Aurora, Colorado. Additional Resources Read the article: Neuropalliative Medicine in Pediatric Neurology Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Smith: This is Gordon Smith. Today I've got the great pleasure of interviewing my good friend Dr Lauren Treat about her article on neuropalliative medicine in pediatric neurology practice. This article appears in the December 2025 Continuum issue on neuropalliative care. Lauren, welcome to the Continuum podcast, and maybe you can introduce yourself to our listeners. Dr Treat: Such a delight to be here, Gordon. Thank you. I am a pediatric neurologist and palliative medicine doctor at the University of Colorado, Children's Hospital Colorado, and I am practicing in both areas. I do general child neurology, and I also run a pediatric neuropalliative medicine clinic. So, I'm happy to be here to talk about it. Dr Smith: And, truth in advertising, I tried very hard to get Dr Treat to move to VC to work with me. And I haven't given up yet. I'm looking forward to the conversation. And Lauren, I wonder- one, I'm really excited about this issue, by the way. This is the second podcast I've done. And I'd like to ask the same question I asked of David Oliver, who's amazing. What a great article and conversation we had. And that question is, can you define palliative care? I think a lot of people think of it as, like, end-of-life care or things like that. And is the definition a little different in the pediatric space than it is in the adult space? Dr Treat: Such a great place to start, Gordon. I absolutely think that there are nuances that are very important in pediatrics. And we especially acknowledge in pediatrics that there is a very longitudinal component of this. And even moreso, I think, then in adult neuropalliative medicine, in pediatrics, we are seeing people=even prenatally or early in their first hours and days of life, and walking with them on a journey that might last days or weeks, but might last years or decades. And so, there is this sense that we are going to come alongside them and be part of the ups and the downs. So yes, neuropalliative medicine is a kind of medicine that is a very natural partner to where neurology is in its current field. We're doing a lot of exciting things with modifying diseases, diagnosing things early, and we have a very high reliance on the things that we can measure in medicine. And not all things can be measured that are worthwhile about one's quality of life. A family very poignantly told me very recently, making sure someone stays alive is different from making sure they have a life. And that's what neuropalliative medicine is about. Dr Smith: Well, great summary, and I definitely want to follow up on several aspects of that, but there's one point I was really curious about as I've been thinking about this, you know, these are really exciting times and neurology in general and in child neurology in particular. And we've got all of these exciting new therapies. And as you know, I'm a neuromuscular person, so it's hard not to think back on SMA and not be super excited. And so, I wonder about the impact of these positive developments on the practice of neuropalliative care in kids. You know, I'm just thinking, you know, you mentioned it's a journey with ups and downs. And I wonder, the complexity of that must be really interesting. And I bet your job looks different now than it did seven or eight years ago. Dr Treat: That's absolutely true. I will self-reference here one of the figures in the paper. Figure 2 in my section is about those trajectories, about how these journeys can have lots of ups and downs and whether this person had a normal health status to begin with or whether they started out life with a lot of challenges. Those ups and downs inherently involve a lot of uncertainty. And that's where palliative medicine shines. Not because we have the answer---everyone would love for us to have the answer---but because we consider ourselves uncertainty specialists in the way that we have to figure out what do we know, what can we ground ourselves in, and how can we continue to move forward even if we don't have all the answers? That is a particular aspect of neurology that is incredibly challenging for families and clinicians, and it can't stand as a barrier to moving forward and trying to figure out what's best for this child, what's best for this family. What do we know to be true about them as people, and how can we integrate that with all of the quantitative measures that we know and love in neurology? Dr Smith: So, I love the comment about prognostication, and this really ties into positive uncertainty or negative undercertainty in terms of therapeutic development. I wonder if you can talk a little bit about your approach to prognostication, particularly in a highly fluid situation. And are there pearls and pitfalls that our listeners should consider when they're discussing prognosis for children, particularly maybe young children who have severe neurological problems? Dr Treat: It's such a pivotal issue, a central issue, to child neurology practice. Again, because we are often meeting people very, very early on in their journey---earlier than we ever have before, sometimes, because of this opportunity to have a diagnosis, you know, prenatally or genetically or whatever else it is---sometimes we are seeing the very early signs of something as compared to previously where we wouldn't have a diagnosis until something was in its more kind of full-blown state. This idea of having a spectrum and giving people the range of possible outcomes is absolutely still what we need to do. However, we need to add on another skill on top of that in helping people anchor into what feels like the most likely situation and what the milestones are going to be in the near future, about how we're going to walk this journey and what we'll be on the lookout for that will help us branch into those different areas of the map down the road. Dr Smith: So, I wonder if we can go back to the framework you mentioned, two answers ago, I think? You and the article, you know, provide four different types of situations kind of based on temporal progression. I wonder if maybe the best way of approaching is to give an example and how that impacts your thoughts of how you manage a particular situation. Dr Treat: Absolutely. So, this figure in particular is helpful in multiple ways. One is to just give a visual of what these disease trajectories are doing, because we're doing that when and we take a history from a patient. But actually, to put it into an external visual for yourself, for your team, but also perhaps for the family can be really powerful. It helps you contextualize the episode of care in which you're meeting the family right now. And it also helps, sometimes, provide some sense of alignment or point out some discrepancies about how you're viewing that child's health and quality of life as compared to how the family might be viewing it. And so, if you say, you know, it sounds like during those five years before we met, you were up here, and now we find ourselves down here, and we're kind of in the middle of the range of where I've seen this person's health status be. Do I have that right? Families feel really seen when you do that and when you can get it accurately. And it also invites a dialogue between the two parties to be able to say, well, maybe I would adjust this. I think we had good health or good quality of life in this season. But you're right, it's getting harder. It's kind of that "show, don't tell" approach of bringing together all the facts to put together the relative position of where we are now in the context of everything they've been through. Dr Smith: You know, I wonder if you could talk a little bit more about the differences between palliative care and adult patients and in children? Dr Treat: Absolutely. One of the key features in pediatrics is this kind of overriding sense of an out-of-order event in the family's life. Children are not supposed to have illness. Children are not supposed to have disability. Children are not supposed to die before their parents. And that layer of tragedy is incredibly heavy and pervasive. It's not every encounter that you have in child neurology, but it does kind of permeate some of the conversations that neurologists have with their patients, especially patients who have serious neurological disease. So that could be things like epileptic encephalopathies, birth injuries, other traumatic brain injuries down the line. In the paper, I'd go through many different categories of the types of conditions that are eligible for pediatric neuropalliative medicine, that kind of support. When we think about that layer of tragedy in the relation to where we're meeting these families, they deserve extra support, not just to think about the medicines and the treatments, but also, what can we hope for? How can we give this child the best possible life in whatever circumstance that they're in? How can we show up in whatever medical decision-making circumstances present themselves to us and feel like we've done right by this child? It's a complex task, and pediatric neural palliative medicine is evolving to be able to be in those spaces with families in a very meaningful way. Dr Smith: So, of course, one of the differences is the, you know, very important role of parents in the situation, right? Obviously, parents are involved in adult palliative care issues and family is very important. But I wonder if you can talk about specific considerations given the parent-child relationship? Dr Treat: So, pediatric neuropalliative medicine really helps facilitate discussions not just about, again, those things that we have data on, but also about what is meaningful and foundational for those families. What's possible at home, what's possible in the community. In pediatrics, parents are making decisions on behalf of their child, often as a dyad, and I don't think this gets enough attention. We know from adult literature that making decisions on behalf of someone else is different from making decisions on behalf of oneself. We call this proxy decision-making. And proxies are more likely to be conservative on behalf of someone else than they are on behalf of themselves, and they're also more likely to overestimate the tolerability of a medical intervention. So, they might say, I wouldn't want this, or, I wouldn't accept this risk on behalf of myself, or, I don't think I'd want to have to persevere through something, but on behalf of this other person, I think they can do it or I will help them through it or something else like this, or, I can't accept the risk on behalf of them. So that's not good or bad. That's just different about making a decision on behalf of oneself as compared to making a decision on behalf of someone else. When there's two people trying to be proxies on behalf of a third person, on behalf of a child, that's a really, really complex task, and it deserves support. And so, pediatric neural palliative medicine can function, then, as this neutral space, as this kind of almost coaching opportunity alongside the other medical doctors to give parents an opportunity when their minds are calm---not in the heat of the moment---to talk about how they see their child, how they've shown up themselves, what they've seen go well, what they've struggled with. And how,, then we can feel prepared for future decision making times, future high-stress encounters, about what will be important to ground them in those moments, even though we can't predict fully what those circumstances might be. Dr Smith: It sounds, you know, from talking to you and having read the article, that these sorts of issues evolve over time, right? And you have commented on this already from your very first answer. And you do describe a framework for how parents think---their mental model, I guess---of, you know, a child with a serious illness. And this sounds like appreciation of that's really important in providing care. Maybe you can talk us through that topic? Dr Treat: I refer to this concept of prognostic awareness in all of the conversations that we have with families. So, what I mean by prognostic awareness is the degree of insight that an individual has about what's currently happening with their child and what may happen in the future regarding the disease and/or the complications. And when we meet people early on in their journey, often their prognostic awareness, that sense of insight about what's going on, can be limited because it requires lived experience to build. Oftentimes time is a factor in that, we gain more lived experience over time, but it's not just time that goes into building that. It's often having a child who has a complication. Sometimes it's experiencing a hospitalization. That transfer from a cognitive understanding of what's going on, from a lived experience about what's going on, really amplifies that prognostic awareness, and it changes season by season in terms of what that family is going through and what they're willing to tolerate. Dr Smith: You introduced a new term for me, which is hyper-capableism. Can you talk about that? I found that really interesting and, you know, it reminds me a lot of the epiphanies that we've had about coma and coma prognosis. So, what's hyper-capableism? Dr Treat: Yes. In neurology, we have to be very aware of our views on ableism, on understanding how we prognosticate in relation to what we value about our abilities. And hyper-capableism refers to someone who feels very competent both cognitively and from a motor standpoint and fosters that sense of value around those two aspects to a high degree. I'm referencing that in the article with regard to medicine, because medicine, the rigors of training, the rigors of practice, require that someone has mental and motor fortitude. That neurology practice and medical practice in general can breed this attitude around the value of skills in both of those areas. And we have to be careful in order to give our patients and families the best care, to not overly project our values and our sense of what's good and bad in the world regarding ableism. Impairments can look different in different social contexts. And when the social context doesn't support an impairment, that's where people struggle. That's where people have stigma. And I think there's a lot of work that we can do in society at large to help improve accommodations for impairment so that we have less ableism in society. Dr Smith: Another term that I found really interesting kind of going back to parents is the "good parent identity." Maybe you can talk about that? Dr Treat: Good parent identity, good parent narrative, is something that is inherent to the journey when you're trying to take care of and make decisions on behalf of a child. And whether you're in a medical context or outside of a medical context, all parents have this either explicit or implicit sense of themselves about what it means to do right by their child. This comes up very poignantly in complex medical conditions because there are so many narratives about what parents ought to do on behalf of their child, and some of those roles can be in tension with one another. It's a whole lot of verbs that often fall under that identity. It's about being able to love and support and take good care of and make good decisions on behalf of someone. But it's also about protecting them from harm and treating their pain and being able to respond to them and know their cues and know these details about them. And you can't, sometimes, do multiple of those things at once. You can't give them as much safety and health as possible and also protect them from pain and suffering when they have a serious illness, when they need care in the hospital that might require a treatment that might be invasive or burdensome to them. And so, trying to be a good parent in the face of not being able to fulfill all those different verbs or ideas about what a good parent might do is a big task. And it can help to make it an explicit part of the conversation about what that family feels like their good parent roles might be in a particular situation. Dr Smith: I want to shift a little bit, Lauren, that's a really great answer. And just, you know, listening to you, your language and your tongue is incredibly positive, which is exciting. But, you know, you have talked about up and downs, and I wanted you to comment on a quote. I actually wrote it down, I'm going to read it to you, because you mentioned this early on in your article: "the heavy emotional and psychological impacts of bearing witness to suffering as a child neurologist." I think all of us, no matter how excited we are about all the therapeutic development, see patients who are suffering. And it's hard when it's a child and you're seeing a family. I wonder if you could talk a little bit about that comment and how you balance that. You're clearly- you're energized in your career, but you do have to bear witness to suffering. Dr Treat: You're right. Child neurologists do incredible work, it's an incredible, exciting field, and there are a lot of challenges that we see people face. And we see it impacts their lives in really intense ways over the course of time. We bear witness to marriages that fall apart. We bear witness to families that lose jobs or have to transition big pieces of their identity in order to care for their children. And that impacts us. And we hold the collective weight of the things that we are trying to improve but sometimes feel less efficacious than we hoped that we could around some of these aspects of people's lives. And so, pediatric neuropalliative medicine is also about supporting colleagues and being able to talk to colleagues about how the care of the patients and the really real effort that we exert on their behalf and the caring that we have in our hearts for them, how that matters. Even if the outcome doesn't change, it's something that matters for our work and for our connections with these families. It's really important. Dr Smith: I wonder, maybe we can end by learning a little bit about your journey? And maybe this is your opportunity to- I know we have students and residents who listen to us, and junior faculty. I think neuropalliative care is obviously an important issue. There's a whole Continuum issue on it---no pun intended---but what was your journey, and maybe what's your pitch? Dr Treat: I'm just going to give a little bit of a snippet from a poem by Andrea Gibson, who's a poet, that I think speaks really clearly to this. They say a difficult life is not less worth living than a gentle one. Joy is simply easier to carry than sorrow. I think that sums these things up really well, that we find a lot of meaning in the work that we do. And it's not that it's easier or harder, it's just that these things all matter. I'm going to speak now, Gordon, to your question about how I got to my journey. When I went into pediatrics and then neuro in my training, I have always loved the brain. It's always been so crucial to what I wanted to do and how I wanted to be in the world. And when I was in my training, I saw that a lot of the really impactful conversations that we were having felt like we left something out. It felt like we couldn't talk about some of the anticipated struggles that we would anticipate on a human level. We could talk about the rate and the volume of the G tube, but we couldn't talk about how this was going to impact a mother's sense of being able to nourish and bond and care for their child because we didn't have answers for those things. And as I went on in my journey, I realized that even if we don't have answers, it's still important for us to acknowledge those things and talk about them and be there for our patients in those conversations. Dr Smith: Well, Lauren, what a great way to end, and what a wonderful conversation, and what a great article. Congratulations and thank you. Dr Treat: Thank you, Gordon. It was a pleasure to be here. Dr Smith: Again today, I've been interviewing Dr Lauren Treat about her really great article on neuropalliative medicine in pediatric neurology practice. This article appears in the December 2025 Continuum issue on neuropalliative care. Be sure to check out Continuum Audio episodes from this issue and other issues. And thanks again to you, our listeners, for joining us today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

A growth charts tell a story long before a child can. A sudden dip, a stubborn plateau, a pubertal spurt that arrives too early, or too late, can spark big questions. From short stature to rapid puberty, it's time to unpack the patterns, pitfalls and possibilities behind pediatric growth. We want to help you sort the reassuring from the concerning and recognize when an endocrinology referral can truly change the trajectory.  Animesh Sharma, MD, specializes in endocrinology at Children's Hospital Colorado, and is an assistant professor at the University of Colorado School of Medicine.   Some highlights from this episode include: The most common growth concerns in primary care  How to identify a growth concern when patients are younger   What workups should be included when referring a patient to endocrinology  Understanding the layers of growth and how to calm parents' nerves  For more information on Children's Colorado, visit: childrenscolorado.org. 

Are we as a population getting dumber? How would we know if we were? This hour: stupidity. We’ll look at the history and philosophy of stupidity, and explore how it shows up in our daily lives and politics. GUESTS: Lane Brown: Features writer for New York Magazine, who recently wrote "A Theory of Dumb" Stuart Jeffries: Journalist and author. His new book is A Short History of Stupidity Shannon Mancus: Teaching Professor and Associate Department Head in the Humanities, Arts, and Social Sciences Department at the Colorado School of Mines. You can follow Dr. Shan on Instagram and Substack at “Pop Smart Media” MUSIC FEATURED (in order): Able Sisters – Animal Crossing New Leaf OST Manchild – Sabrina Carpenter Dumb All Over – Frank Zappa Get Stupid – Aston Merrygold How Sweet to Be an Idiot – Neil Innes Idiot Wind – Bob Dylan Support the show: http://www.wnpr.org/donateSee omnystudio.com/listener for privacy information.

In this Complex Care Journal Club podcast episode, Drs. Reshma Amin and Christopher Baker discuss a clinical practice guideline from the American Thoracic Society on the care of infants and children with tracheostomies. They describe the role of interprofessional and family-centered decision-making, safety- and ethics-driven recommendations, and next steps for implementation across diverse healthcare settings. SPEAKERS Reshma Amin, MD, MSc Staff Respirologist, Director of Sleep Medicine and Long-term Ventilation The Hospital for Sick Children Senior Associate Scientist, SickKids Research Institute Professor, The University of Toronto Christopher D. Baker, MD Director, Ventilation Care Program, Children's Hospital Colorado Professor of Pediatrics - Pulmonary Medicine University of Colorado School of Medicine HOST Kilby Mann, MD Associate ‌Professor Pediatric Rehabilitation Medicine Children's Hospital Colorado DATE Initial publication date: January 13, 2026. JOURNAL CLUB ARTICLE Amin R, Agarwal A, Chiang J, Collaco JM, Cristea AI, Propst EJ, Sobotka SA, Balakrishnan K, Benscoter D, Brenner MJ, Castro-Codesal ML, Cuevas Guaman M, Daines CL, Dawson JA, Edwards JD, Graham RJ, Henningfeld JK, Hoekstra NE, Jackson AJ, Johnson RF, Kam K, Kun SS, Napolitano N, Pacheco A, Panitch HB, Prager JD, Shi JY, Soma M, St-Laurent A, Syed F, Watters KF, Zielinski D, Ho ATN, Velagapudi RK, Zeba F, Knight SL, Iyer N, Baker CD. Care of Infants and Children with Tracheostomies: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2025 Nov;211(11):2001-2020. doi: 10.1164/rccm.202508-2055ST. PMID: 41123183; PMCID: PMC12618984. OTHER ARTICLES REFERENCED Sherman JM, Davis S, Albamonte-Petrick S, Chatburn RL, Fitton C, Green C, Johnston J, Lyrene RK, Myer C 3rd, Othersen HB, Wood R, Zach M, Zander J, Zinman R. Care of the child with a chronic tracheostomy. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan;161(1):297-308. doi: 10.1164/ajrccm.161.1.ats1-00. PMID: 10619835. ‌ Sterni LM, Collaco JM, Baker CD, Carroll JL, Sharma GD, Brozek JL, Finder JD, Ackerman VL, Arens R, Boroughs DS, Carter J, Daigle KL, Dougherty J, Gozal D, Kevill K, Kravitz RM, Kriseman T, MacLusky I, Rivera-Spoljaric K, Tori AJ, Ferkol T, Halbower AC; ATS Pediatric Chronic Home Ventilation Workgroup. An Official American Thoracic Society Clinical Practice Guideline: Pediatric Chronic Home Invasive Ventilation. Am J Respir Crit Care Med. 2016 Apr 15;193(8):e16-35. doi: 10.1164/rccm.201602-0276ST. PMID: 27082538; PMCID: PMC5439679. ‌ TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/wkhzg7pznk5cgb23sk9xg7w7/Amin_and_Baker_Final_transcript_1-9-26_kh_ra_Baker Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: https://forms.gle/Bdxb86Sw5qq1uFhW6. Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Amin R, Baker CD, Mann K. Balancing Safety, Practicality, and Equity in Pediatric Tracheostomy Guidelines. 1/2026. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/balancing-safety-practicality-and-equity-in-pediatric-tracheostomy-guidelines.

With President Trump's moves to take control of Venezuela's oil production—including the seizure of incoming and outgoing oil tankers—there's been a lot of talk about the country's deep reserves of crude. But not all oil is the same, and getting the Venezuelan reserves out of the ground might be neither cheap nor simple. So who wants that oil, and what is it good for?Petroleum engineer Jennifer Miskimins joins Host Ira Flatow to drill into the ABCs of oil production and refining.Guest: Dr. Jennifer Miskimins is 2026 president of the Society of Petroleum Engineers, and head of the petroleum engineering department at the Colorado School of Mines in Golden, Colorado.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dr. Natalia Vergara is an Assistant Professor of Ophthalmology at the Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine on the Anschutz Medical Campus. Natalia uses stem cells to understand how the retina forms during development and how it degenerates during disease with the goal of developing therapies to help patients who suffer from vision loss. For her research, Natalia uses a type of stem cells called induced pluripotent stem cells which can be reprogrammed so they can form any type of cell in the body. With these cells, they can make human retina tissue using any individual's cells in a petri dish in the lab to better understand diseases, test treatments, and potentially prepare retinas for transplant. In her free time, Natalia loves hanging out, cooking, and enjoying food with friends and family, including her husband and two young kids. Natalia is also an avid traveler, and she delights in the thrill of discovery that comes along with exploring new places. Natalia received her B.S. in biochemistry from the National University of the Litoral in Argentina. She worked as an instructor and research intern at the National University of Entre Ríos for about three years before beginning graduate school. Natalia was awarded her PhD in retinal regenerative biology from Miami University in Ohio. Afterwards, she conducted postdoctoral research at the Wilmer Eye Institute of Johns Hopkins School of Medicine. She served as a Research Associate Faculty member at Johns Hopkins School of Medicine for about two years before joining the faculty at the University of Colorado. Natalia has received awards for research and for mentoring, including the Ruben Adler Research Award from the Wilmer Eye Institute at Johns Hopkins University School of Medicine in 2012, and she was selected as an Emerging Vision Scientist to participate in the Third Annual EVS day on Capitol Hill by the National Alliance for Eye and Vision Research in 2017. In our interview, Natalia tells us more about her life and science.

Anxiety in children can serve as a safeguard or become profoundly disruptive. For pediatricians, distinguishing between developmentally appropriate worry, generalized anxiety disorder and clinically significant anxiety is rarely straightforward. In this episode, we explore how anxiety presents across childhood, why it is more than "just nerves" and how pediatricians can play a key role in early identification and support.  Benjamin Mullin, PhD, is the lead psychologist of the Colorado OCD and Anxiety Program (COAP) at Children's Hospital Colorado, as well as an associate professor at the University of Colorado School of Medicine. He is also the Leslie and William Vollbracht Family Chair in Stress and Anxiety Disorders.  Some highlights from this episode include:  The realities of anxiety in kids  When treatment is appropriate and when to refer   Helping families understand anxiety without stigmatizing or minimizing their children's experience  Strategies that work for long-term management   For more information on Children's Colorado, visit: childrenscolorado.org. 

Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USANow, with our collective experience, we can at least put together the information that we have in terms of what can we expect and what's the timeline that we expect in terms of our patients having reactions. I will tell you, and I've said this multiple times, when I deliver a gene transfer therapy, I hold my breath for 2 months. Now, maybe it's going to have to be extended to a year, but it's typically at least for 2-3 months. It's like, okay, what's going to happen? You sit on the edge of your seat on pins and needles, going, "Is this kid going to be okay or not?" I think that's the appropriate response to have in terms of the light of things that have happened over time. We have to be really careful.We have a little bit of a framework now to say, when do we need to be really excited? We know that our patients, most all of them, are going to develop a transaminitis, and that ends up happening early on, but we get a couple of peaks. We get really excited that the 4-8 week time point with transaminitis looking for liver failure.The cholestatic liver disease that happened in the patients with X-linked MTM happened a little bit later, so Week 2, all the way out to six months afterwards. The acute cardiomyopathy a little bit earlier, so we're looking a little bit earlier for that effect. TMA, usually the end of the first week to about 2 weeks is when we would expect that to come in. Then the transgene-related myositis and immune-mediated myocarditis, weeks, maybe 2 to a couple of months.How do we adapt our gene transfer programs to the clinical trial experience? I think that there are a couple of points that are important. One is that the outline that I showed you, there are some disease-agnostic issues that come up with transaminitis, with TMA. I think there are some final common pathways related to the immune responses that we see with these patients. Then there are going to be some disease-specific disorders that are going to come up with each of these therapies and agents.We need to have good communication, honestly, in real-time. I still don't know that we have a good mechanism for that as a community, but to share these adverse events that come up so that we can all learn as a collective about what to expect, what to anticipate, and how to best take care of our patients. We know now how we need to monitor patients closely from a laboratory standpoint, from a clinical exam standpoint, and we really need to work on how are we going to mitigate some of these risk issues that we have with these patients.I think the collaborative aspect, particularly at meetings like this, is important. Last year, for the people that were at MDA, you remember that we really spent a lot of time looking at gene transfer delivery. Many of us got together as providers and actually met together to say, "Is there something that we can think about in terms of best practice or consensus in terms of how we would want to manage patients or how we'd want to share information?"Now, actually, on the MDA website, we really do have some guidelines, and there will be a publication coming out shortly that we'll have this available to everybody again. It's not necessarily the right answer, but it's at least from a collective experience, what's the best way that we can go forward? Some of the suggestions were that the adverse events right now, we can put them into some a predictable timeline, but we don't really know all the risks at the time of dosing.We know that gene transfer therapy can be safe for the right patient at the right time for the right disorder. That's really what we want to do. There's a Neurotherapeutic window between efficacy and toxicity. How are we adjusting that? What are we working on to make sure that we're getting that right? The preclinical data is helpful, but it's never the full story. Any time we go from a homogeneous population that we see in a clinical trial to a heterogeneous population, as we throw this out to the world, we're going to have new issues that arise, and we need to be aware and ready for those.We want to be able to predict what happens, but we can't always do that. Then follow-up is so important. The post-marketing study, sharing adverse events, sharing experiences, I think, is really important as well. Clinicians really should be familiar with this entire field before ever delivering gene transfer therapy. I don't think that every site should be delivering gene transfer. I think that from an institutional standpoint, you need to be ready. You need to have a team who knows what they're doing and knows how to handle the issues and the problems, or you need to have lifelines set up in advance if you're going to deliver these treatments.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe ASPIRO Clinical Trial is on clinical hold since September 2021. In this part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.Question: Is there a standardized immunomodulation regimen being considered for gene therapy?Julie A. Parsons, MDAs I mentioned, right now, I think there are a number of different concepts that are being utilized. We don't really have a recommended standard regimen at this point. There are a number of different trials that are ongoing looking at trying to answer this question. In some of the clinical trials, there is an immune modulating regimen that is being put in place but being looked at. There isn't anything that we have as a standard at this moment for all gene transfer therapies, but I'm hopeful that we will come up with something that really makes sense in each patient population as we go forward with specific gene transfer therapies.Question: What are the long-term implications, safety and efficacy of a one-time gene therapy in pediatric patients with neuromuscular diseases?Alan Beggs, PhDOne question is the efficacy. For example, Donovan Decker's story, he had an experimental treatment of one muscle. It was a phase one safety trial, and he knew that nothing was going to come of it in terms of direct benefit to him. As a result, though, 25, 30 years later, he still has a tighter against AAV vectors. He's not a candidate for gene therapy under current protocols, although there's a lot of work going on to redosing. But for now, it's a one-time treatment. What you get is what you get, and there's not a chance to go back and do it again.The other question is durability. We really don't know about the long-term durability for these treatments. I should say that, for example, in the studies that we did, David Mack, who's here in the audience, managed a dog colony for a dog model of excellent tubular myopathy. Those animals lived 10 years in a... We never used the C-word, but they were cured. They were healthy, happy, normal dogs who would have had to be put down at 6 months of age otherwise. And then, as we heard, I'll let you talk about the concern for unanticipated SAEs as time goes on, but I think there's other aspects we need to think about.Julie A. Parsons, MDYeah. I think that this is really the key question that all of us are going to need to help answer over the next several years. Efficacy, we're looking at outcomes, and outcomes come in a variety of flavors. I think we do a decent job with motor outcomes. We don't do a decent job with some other outcomes. I think we need to look more broadly in terms of what we mean in terms of beneficial outcomes and really take some of those cues from the patients themselves about if these are efficacious treatments, because, again, the risk is high as we deliver these agents, and we need to know that it's worth it to the patients and families.In terms of safety, we're working on it. There are all sorts of things that are coming forward as issues with these patients. I think that collectively as a community, that our responsibility is to follow patients for the long term. There are lots of registries and outcome studies. We're not very good as a community about reporting adverse events to central groups. We're not great about broadcasting that to each other in real-time. I think those are things that we really need to work on as a community in terms of helping with the safety issues so that we all have a communal better understanding of what some of those issues are.

Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAHow have programs adapted to the experiences from clinical trials? I'm just looking at SMA because we've had SMA. We've had onasemnogene around for the longest period of time. We want to always confirm a diagnosis and know that the patient is right. We do antibody testing for these disorders prior to delivering the AAV therapies. We have to know that the product that is incredibly expensive is handled appropriately by the institution. Dealing with the pharmacy, making certain that you handle the agent properly, patients need to be pretreated at this point with prednisone, and that really has to happen so that you know that they're ready for treatment, that they don't have any infections prior to treatment.Then we need to monitor and provide medication and follow-up afterwards. As I said, I think this is really, really important to make sure that you're connected well with the patient. If you live in an area as we do, that has a huge catchment area with patients that come from hundreds of miles away, sometimes they need to stay with us for a period of time, so that we can ensure the safety and follow-up of these patients after we deliver gene therapies.Again, a recurring theme is the patients that you're treating who are not in a clinical trial are not the homogeneous, well-selected patients. It's really all actors. The population that you're treating commercially is very different. We're now moving into treating patients with larger body masses and older ages. We don't always know, because those patients haven't really been included in the clinical trials. We don't really know what some of the effects are going to be with that group of patients as well.I am a neurologist. I am not an immunologist. I have had to learn a lot of immunology at this point, but it's still not sufficient. I think that we also need to reach out to our subspecialist colleagues who really do have more experience than we do to try to help us with some of these issues, because as we look at these viral vector capsids and the transgenes, we have to say, is there something that we can do to mitigate the immune response that we're seeing when we're giving massive doses of these agents and really taxing the immune system in our patients?Looking at possibilities, we give steroids, and that's really what we've done. That was what was done in the early clinical trials with MENDEL. It's like, okay, prednisone, that's all we have to do is we give steroids and everybody will be fine. That really isn't maybe the answer. As we have more information, we know that we're going to start with steroids, but we're really going to look at, is there a way to block both the B-cell response, the T-cell response? Is there something that we can do so that we don't have to sit on the edge of our seats and not sleep for months after we treat these patients?At least in a trial, was done looking at patients who were treated just with corticosteroids. Those patients had rapid increases in IgM and IgG. There's complement activation. Both the adaptive and the acute immune responses are triggered. That's really what we're doing as standard practice right now, but in the trial looking at treating patients and pretreating patients with rituximab blocking B cells and sirolimus and corticosteroids, then no significant change in IgM, IgG.Is that something that we should be doing? I think that some of the clinical trials that are being set up are looking at instituting some of these immune-modulating features to see whether or not their outcomes are improved. Can we do anything proactively to prevent our patients from having some of these very severe events or fatalities? I think that's really what we need to be looking at now. I think we are looking at that as a community, and to me, is a story that is still unfolding in terms of how we keep our patients safe.In the next part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.

Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAAs we talk about the gene transfer therapies and the modalities that we have to use, it's really interesting. Yesterday, with our keynote speaker, you could see this logarithmic growth of the use of gene transfer therapies for these disorders. If you look at the Venn diagram, you can see that really 27% almost of gene transfer therapies that are used are in musculoskeletal and neurology. For many of us as neurologists, we also take care of metabolic disorders.We really own right now this landscape, and of course, our two approved modalities are Onasemnogene and Delandistrogene. We're going to look at three different disorders, monogenic disorders, monogenic diseases, to typify what we look at in terms of some of the risks and benefits of these treatments. SMA, Duchenne, and X-linked myotubular myopathy are all rare disorders. They're all diseases that have a high unmet medical need and a significant disease burden.I think they're all good in terms of typifying where we are clinically with these disorders. The first question is, is it worth it? Are these effective treatments? We know from looking at the information about SMA that just looking early on, we know that if we treat kids early, that we do see a marked improvement in motor scores for kids that are treated early with Onasemnogene.In Duchenne, we have information that there is at least some improvement in the 4-5-year-olds in terms of motor skills treated with Delandistrogene. In terms of X-linked MTM, which was a very dramatic improvement, you could see that for boys who were basically traked, vented, and had no mobility, the bottom line, the blue line, is actually looking at ventilator dependence. Are they effective? Yeah, they're effective, but then we have to say, okay, what's the downside?The downside is that there's tremendous risk associated with treatment with these agents. If we really look at the sobering facts, we know that with SMA, there have been deaths, there have been fatalities related to thrombotic microangiopathy to patients who have liver failure, a couple of patients have died. With Onasemnogene, this is 4,000 plus doses that have so far been given. With Duchenne, unfortunately, many of us got the letter yesterday talking about an additional death in a patient treated with commercial Delandistrogene.We also know with some of the other agents, like fordadistrogene, patient died of heart failure, cardiac arrest, another patient who had acute respiratory syndrome with pulmonary edema. Again, we look at this and say this is significant. With X-linked MTM, as Alan said, there were some unanticipated deaths, four deaths from patients who ended up having cholestatic liver diseases that really wasn't anticipated prior to the patients being treated with the animal models and all that we had. Then many of you have heard about the patient with Rett syndrome who had a systemic hyperinflammatory syndrome. Again, these are rare disorders. They have a high disease burden, but the risk of treatment is significant.In the next part, Dr. Parsons discuss factors impacting safety and efficacy of AAV-mediated gene therapies.

Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe gene transfer trials for musculoskeletal disorders, if we look at musculoskeletal and neurologic disorders, we really do have the highest success rate in terms of treatment, but we also carry the highest incidence of treatment-emergent severe adverse events. And why is that true? Yesterday, when we were hearing about Donovan as well, we looked and said, When the first gene transfer therapies were started, he had a single muscle that was injected.When we look at Luxturna, we injected the retina. Now, what is happening with these disorders is that we're giving these huge, massive doses of viral vector to patients. There haven't been a lot of gene transfer therapies that have reached the market. But you saw yesterday, so many gene transfer therapies being worked on, but there are very few that have actually come to market. There are a couple of reasons for that.One is with the indications that we have, we know that the musculoskeletal disorders are most likely to achieve benefit, but there are the high risk of severe adverse events. Route of Administration, IV, for most of our disorders is the way we're going. We may end up having some Intrathecal therapies as well that are coming on board, but right now it's IV, and that means, a huge dose of this viral vector and antigenic risk that is being administered.In the vector design now, we actually have more specific vectors as well as promoters that are being utilized to really target specific tissues, so that we're able to focus in a little bit more on the tissues that we want to have affected. And then the dose has gone from these little tiny local injections to really systemic, much broader. And now our patients, are larger. So we're giving a viral genome per kilo dose that is just massive as we look at that.Then there really are challenges in terms of the translation of clinical trials to commercial treatment with these agents. And we don't always know, we're not always great when we do tests in clinical trials in small populations, about when that's broadened to the commercial availability and we hit larger heterogeneous populations.There are safety issues arising from these therapies, and I think that we have some experience now, certainly with the three diseases that I mentioned at the beginning, in terms of collecting some data and information to have a little bit more of an idea what to expect. Although to me, the recurring esteem is always, expect the unexpected. Because we still are learning about this. Hepatotoxicity. We know that transaminitis is something that we see in almost every gene transfer therapy that has been delivered, and we have to watch really, really closely and follow our patients closely for this. We also have to select patients that we don't think have risk for additional liver injury or underlying liver pathology, because as we found out in the XLMTM boys, we missed that. Thrombotic Microangiopathy. We look at this disorder. We've had deaths in SMA from TMA. We have Duchenne patients that have had TMA.This is scary because as many of us as clinicians who have treated patients, you know that we end up getting thrombocytopenia. So is that it this time, or are they going to be fine, or the platelet is going to go back to normal? This is another one that we have to watch really, really closely for. Cardiac Toxicity. We have had cardio myositis. We've had deaths from cardiac toxicity.Something really, really important for us to think about. In little kids, vomiting could be a sign of cardiac myositis. And for most of us who've treated patients with gene transfer therapy, what's one of the first issues that you get?You get nausea of vomiting, they don't feel good. So is that myocarditis or is it just a standard side effect that we're seeing with treatment? Importantly, as we discovered, there actually can be an immune response to the transgene. It's not just the viral vector capsid, it's actually the transgene as well. That was discovered in patients who were treated for Duchenne. So that's a really important thing in terms of looking now at what's our patient's selection and how do we pick the right patients.Next part, Dr. Parsons will discuss understanding and preparing risk factors associated with AAV gene therapies.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USADoctors Beggs and Parsons discuss the current status of gene therapies in rare neuromuscular disorders in this eight part podcast series. This is derived from the symposium that was presented at the MDA 2025 conference in Dallas, Texas, in March 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established. In contents of this podcast, shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The ASPIRO clinical trial is on clinical hold since September 2021.In this part, Doctor Beggs will provide an explanation of AAV-mediated gene therapies.Alan Beggs, PhDAAV vectors, which I'm going to be talking about more today, or Adeno associated viral vectors are small viruses. Their DNA gets delivered into the cell and remains extrachromosomal. There are very rare occasional integrations, but the risk of oncogenesis as a result is significantly lower as a consequence of remaining extrachromosomal, though, we do have to think about what happens as the cells divide and potentially the durability of treatment is more limited.There have been a lot of movement and development over the years, starting back in the 1980s when the first AAV genomes were isolated and sequenced. This led to a development of methods to produce recombinant AAVs that would lack the genes necessary for viral replication, but contain a therapeutic gene you wish to deliver. Through this, the structure of AAVs have been developed. There have been isolation of a number of naturally occurring variants. You've heard of AAV8, AAV9, also RH 74, derived from a rhesus monkey for the RH. These have all been used in clinical trials. Then at the end I'll talk a little bit about directed evolution methods to actually engineer capsids with particular properties that are beneficial.Throughout this we've identified some of the issues that arise in this. It was initially thought that AAV vectors were non-immunogenic, but in fact there are immune responses not just to the viral payload to the therapeutic protein, but also to the viral vectors, and you're going to hear about that from Doctor Parsons. Over time, as we've come to understand these challenges, we've also been developing approaches to mitigate them. In terms of clinical trials and treatments, the very first studies were done back in the 1970s.By the early 2000, the very first clinical therapeutic was approved in China. It was actually an oncolytic virus carrying a p53 gene to treat head and neck cancers. By now there are over 40 approved treatments for various types of AAV delivered gene therapies. Of course, the ones we know a lot about are Zolgensma, which was approved in 2019, and Elevidys, which was approved last year. A number of challenges and then also a number of approaches to overcome those challenges. First of all, the preclinical data are not always sufficient to predict the response of a human patient.For example, in X-linked myotubular myopathy we had mouse and dog models that exhibited a myopathy but nothing else, and yet when we treated human patients, we discovered that patients with X-linked myotubular myopathy actually had a previously only poorly recognized hepatopathology that led to potential liver consequences following gene therapy. The animal models don't always predict the clinical outcome in humans.Also, we have small disease populations. These are rare diseases. It's important to understand the natural history of these diseases, understand the heterogeneity among the clinical population. It's very important to engage with families and with patients and communities, understand who might be at increased risk to treatment with one of these. This feeds into safety considerations. We need to think also about some of the immune responses. I think we're starting to learn, for example, with the gene therapies for Duchenne, and we know this from SMA that some patients get into trouble and others don't. We need to understand why that may be, and we don't know about the long term effects. This has been very recent.

In pediatric practice, few topics are as foundational and scientifically grounded as vaccinations. This season, a major shift in federal vaccine advisory guidance has sparked fresh discussion about how we protect infants from hepatitis B. The Center for Disease Control and Prevention's advisory committee on immunization practices voted to revise the more than 30-year guidance around the universal birth-dose of the Hepatitis B vaccine. In this episode, our goal is to provide clarity for clinicians on the best vaccination approach for our youngest patients.  For this important discussion, we are joined by Sean O'Leary, MD, a pediatric infectious disease specialist at Children's Colorado, as well as a professor at the University of Colorado School of Medicine. He is also chair of the American Academy of Pediatrics (AAP) Committee on Infectious Diseases, otherwise known as the Red Book Committee.  Some highlights from this episode include: The history of hepatitis B infection in children in the U.S.  Why the birth dose has been such a critical part of prevention  Breaking down the recent decision by the CDC advisory committee  Recommendations for this vaccine moving forward For more information on Children's Colorado, visit: childrenscolorado.org. 

In this episode, Dr. Jialuo He, Research Assistant Professor at Washington State University, and Dr. Lori Tunstall, Assistant Professor at the Colorado School of Mines, share the unique paths that led them into civil and environmental engineering. Dr. He reflects on his shift from polymer materials to pioneering work in self-healing concrete, tracing an academic journey that spans multiple institutions and research disciplines. Dr. Tunstall discusses her unexpected move from an English major to an engineering career fueled by a deep curiosity for concrete materials and their real-world applications. Together, they highlight the power of interdisciplinary learning, the role of curiosity in shaping research trajectories, and the importance of professional networks—especially through the American Concrete Institute. The conversation offers a forward-looking perspective on the rapidly evolving field of concrete materials and the innovative approaches shaping its future. Check out the video podcast here: https://youtu.be/ouLY6RnHZqY   Engineering Greatness is produced by Association Briefings. 

Send us a textAbout D. Kaleb AbbottDr. Kaleb Abbott is an optometrist and assistant professor of ophthalmology at the University of Colorado School of Medicine. He is affiliated with both the Dry Eye Clinic and the Center for Ocular Inflammation, where he specializes in complex ocular surface diseases and participates in clinical trials and research related to these conditions. In addition to his clinical and research roles, he serves as vice-president for the Ocular Wellness and Nutrition Society, is Chair of the Nutrition, Disease Prevention, and Wellness Special Interest Group (SIG) for the American Academy of Optometry (AAO), and is a member of the advisory council for the Academic Medical Center Optometry AAO SIG. He also holds a position on the editorial advisory board for Modern Optometry and Optometry360 and is a graduate of the AAO Flom Leadership Academy. Furthermore, he hosts the Dry Eye and Ocular Surface Disease section of the Clinical Podcast Series through the American Academy of Optometry Foundation. In 2024, he was nominated for Colorado's Young Optometrist of the Year and recognized as a “One-to-Watch” by Modern Optometry.In 2019, Kaleb co-founded SunSnap Kids, a start-up that won first place in the inaugural Bright Ideas Pitch Competition in 2022 and third place in the Optometry Innovation Awards in 2023. He recently sold the majority of the company to focus more on his clinical and research responsibilities at the University of Colorado.When he's not seeing patients, conducting research, or working on SunSnap Kids, Dr. Abbott lectures on ocular surface diseases, writes articles, and serves as a medical reviewer for multiple journals, including The Ocular Surface and Optometry and Vision Science. He resides in Denver, CO, with his wife, daughter, and newborn twins.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com What happens when clinicians have groundbreaking ideas, but no roadmap to bring them to life? In this episode, Dr. Arlen Meyers, Professor Emeritus of Otolaryngology, Dentistry, and Engineering at the University of Colorado School of Medicine and the Colorado School of Public Health, and President and CEO of the Society of Physician Entrepreneurs, discusses how SOPE helps clinicians transform ideas into innovations that reach patients. He explains why most healthcare professionals lack formal entrepreneurship training and how that gap leaves them unsure of what to do with their ideas. He explores the rising challenges of burnout and moral injury in medicine, and how fear, ego, and identity keep many clinicians from pursuing new paths. He also shares how SOPE uses “radical candor,” idea euthanasia, and practical entrepreneurial frameworks to help innovators pivot, persevere, or let go. Tune in to hear how physician innovators can finally connect the dots! Resources Connect with and follow Dr. Arlen Meyers on LinkedIn. Follow the Society of Physician Entrepreneurs on LinkedIn and discover their website!

Drs Kaniksha Desai and Whitney Goldner discuss a new guideline approach for active surveillance for selected patients with low-risk papillary thyroid cancer. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0 Kaniksha Desai, MDAssociate Professor of Medicine, Department of Endocrinology, Stanford School of Medicine, Palo , Whitney S. Goldner, MD, Professor; Head, Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado

On this episode, Dr. Nolan Wessell, Assistant Professor and Well-being Co-Director, Department of Orthopedic Surgery, Division of Spine Surgery, University of Colorado School of Medicine joins the podcast to discuss the growing burden facing the spine field and how clinicians are adapting to rapid shifts in practice and policy. He shares insights on tracking government changes that impact research funding, the ways AI is improving efficiency and supporting clinical decision-making, and the consequences of declining reimbursements across the specialty.

On this episode, Dr. Nolan Wessell, Assistant Professor and Well-being Co-Director, Department of Orthopedic Surgery, Division of Spine Surgery, University of Colorado School of Medicine joins the podcast to discuss the growing burden facing the spine field and how clinicians are adapting to rapid shifts in practice and policy. He shares insights on tracking government changes that impact research funding, the ways AI is improving efficiency and supporting clinical decision-making, and the consequences of declining reimbursements across the specialty.

On this episode, Dr. Nolan Wessell, Assistant Professor and Well-being Co-Director, Department of Orthopedic Surgery, Division of Spine Surgery, University of Colorado School of Medicine joins the podcast to discuss the growing burden facing the spine field and how clinicians are adapting to rapid shifts in practice and policy. He shares insights on tracking government changes that impact research funding, the ways AI is improving efficiency and supporting clinical decision-making, and the consequences of declining reimbursements across the specialty.

Childhood obesity management has evolved far beyond the traditional advice of "eat healthier and move more." Today's clinical toolbox includes GLP-1 medications, behavioral health interventions, multidisciplinary lifestyle programs and bariatric surgery. These evidence-based tools can be complex, nuanced, and sometimes controversial, but they share a common goal: supporting young people in achieving healthier lives. In this episode, we explore how modern treatment strategies come together to meet the needs of individual patients and families. Our guests discuss when and how to use these tools, the importance of coordinated care and what pediatricians should consider as this field continues to rapidly expand. Jonathan Hills-Dunlap, MD, is the Director of Robotics Surgery as well as the Surgical Director of the Bariatric Surgery Program at Children's Colorado. Megan Kelsey is the Medical Director of both Lifestyle Medicine and the Adolescent Bariatric Surgery Program. Both are on faculty at the University of Colorado School of Medicine. Some highlights from this episode include: The steps for being a bariatric surgery candidate How to best support obese patients and their journeys  Why a multidisciplinary approach is necessary For more information on Children's Colorado, visit: childrenscolorado.org. 

Recently, leucovorin and acetaminophen have been at the center of new discussions in pediatric medicine. Could leucovorin really help some children with autism? Does the latest evidence suggest acetaminophen has any impact on neurodevelopment? In today's episode, we'll break down what the science actually tells us, what remains uncertain and how pediatricians can confidently guide families through these complex topics. Joining us for this important discussion is Abigail Angulo, MD. She is a developmental-behavioral pediatrician at Children's Hospital Colorado. She is also an associate professor at the University of Colorado School of Medicine. Some highlights from this episode include:  The science behind autism  The role of Tylenol in pregnancy and newborn development  What leucovorin is used for and when it should be prescribed  How to navigate difficult conversations with families who expect certain outcomes For more information on Children's Colorado, visit: childrenscolorado.org. 

ORAU coordinates the evaluation of DOE former workers through the National Supplemental Screening Program. Through the NSSP, the U.S. Department of Energy offers free customized medical screenings to their former workers who may have been exposed to hazardous substances on the job site. On this episode of Further Together, host Michael Holtz and Wendy Benade, operations manager, and Heather O'Maonaigh, outreach manager, take a deep dive into the program, from outreach to enrollment and so much more. ORAU manages the program along with great partners, including National Jewish Health, Acuity International, Cority Software, and the Center for Health, Work & Environment at the Colorado School of Public Health. Former workers include eligible DOE federal, contractor, and subcontractor workers. The screenings are designed to identify findings consistent with occupational diseases such as chronic respiratory illnesses, hearing loss, kidney or liver disease, and some forms of cancer. Since the program was established in 2005, more than 22,500 initial exams of former workers have been conducted, and more than 11,000 follow-up exams. To learn more about the NSSP and the various former worker programs, visit: DOE Former Worker Medical Screening Program (FWP) website: https://www.energy.gov/ehss/former-worker-medical-screening-program-0 Find Your Program Tool on the DOE FWP website: https://ehss.energy.gov/FWP_findyourprogram/ NSSP website: https://orau.org/nssp NSSP phone number (toll-free): 1-866-812-6703

Akasha J. Smith, PhD is the founder of School of Awakening which offers The Professional Intuitive Healer Certification Program and Transformational Retreats in Bali and Costa Rica. She's been Teaching,  facilitating Intuitive Healing sessions, Transpersonal Counseling and Past Life Regressions for people around the world for more than 20 years. She also offers Akashic Records Readings and Channeled Awakening Transmissions.One of her favorite parts about the work is watching people's hearts, bodies, minds and souls open to the connection and lives they've been so deeply longing for. When someone is ready and really shows up, true healing simply happens. With that can come a freedom unlike anything else that is absolutely beautiful to witness…another human shining.Akasha's Soul Purpose is to Help People Remember and Be Who they Truly Are. She does this through teaching, healing and creative expression. She is Deeply Passionate about Teaching Intuitive People, even if they Doubt their Abilities, how to Become Professional Healers, Heal Themselves and Awaken. Akasha has taught everything from Human Development Psychology to Creativity Enhancement and Dance to How to Connect with your Spirit Guides.She taught Mindfulness Meditation in Naropa University's Graduate Transpersonal and Contemplative Psychology Counseling Programs. Akasha researched Passionate Engagement for her Doctorate in East West Psychology at The California Institute of Integral Studies. She has a Masters Degree in Psychology from The Institute of Transpersonal Psychology with specializations in Teaching, Education & Research and Creative Expression. Akasha graduated from Naropa University with a Bachelor's degree in Contemplative Psychology and minors in Traditional Eastern and Healing Arts and Improvisational Dance. She also trained in The Clairvoyant Program at Psychic Horizons Institute and The Colorado School of Transpersonal Counseling and Hypnotherapy where she became an internationally certified hypnotherapist. She completed her yoga teacher training in Rishikesh, India and has studied traditional dance in Bali, Thailand, Hawaii and Spain.Akasha is a best-selling contributing author of Activate Your Life and just finished contributing to a 2nd book on Awakening Experiences and their impact on daily life. She was the co-author of a Transformation from Trauma study which was published in the peer-reviewed academic journal, The International Journal of Transpersonal Psychology.When Akasha isn't helping people Become Counselors and Healers and Leading Retreats, she's Creating Lightcode Art, Writing Poetry or Traveling the World Solo studying Dance, Healing and Yoga. https://www.schoolofawakenedliving.com/

Send us a textThis discussion features Dr. Clyde Wright, Professor of Pediatrics at Children's Hospital Colorado and the University of Colorado School of Medicine, who studies perinatal innate immunity and neonatal lung injury. He highlights the rapid rise of acetaminophen as the most commonly used medication for ductal closure in preterm infants despite limited long-term safety data. Dr. Wright explains how acetaminophen metabolism via CYP2E1 produces a reactive metabolite that may affect mitochondrial function in developing lung cells, prompting consideration beyond hepatic toxicity markers. He encourages clinicians to remain judicious, especially outside optimal treatment windows, and calls for research incorporating respiratory outcomes and nuanced, individualized risk–benefit discussions at the bedside.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Akasha J. Smith, PhD is the founder of School of Awakening which offers The Professional Intuitive Healer Certification Program and Transformational Retreats in Bali and Costa Rica. She's been Teaching,  facilitating Intuitive Healing sessions, Transpersonal Counseling and Past Life Regressions for people around the world for more than 20 years. She also offers Akashic Records Readings and Channeled Awakening Transmissions.One of her favorite parts about the work is watching people's hearts, bodies, minds and souls open to the connection and lives they've been so deeply longing for. When someone is ready and really shows up, true healing simply happens. With that can come a freedom unlike anything else that is absolutely beautiful to witness…another human shining.Akasha's Soul Purpose is to Help People Remember and Be Who they Truly Are. She does this through teaching, healing and creative expression. She is Deeply Passionate about Teaching Intuitive People, even if they Doubt their Abilities, how to Become Professional Healers, Heal Themselves and Awaken. Akasha has taught everything from Human Development Psychology to Creativity Enhancement and Dance to How to Connect with your Spirit Guides.She taught Mindfulness Meditation in Naropa University's Graduate Transpersonal and Contemplative Psychology Counseling Programs. Akasha researched Passionate Engagement for her Doctorate in East West Psychology at The California Institute of Integral Studies. She has a Masters Degree in Psychology from The Institute of Transpersonal Psychology with specializations in Teaching, Education & Research and Creative Expression. Akasha graduated from Naropa University with a Bachelor's degree in Contemplative Psychology and minors in Traditional Eastern and Healing Arts and Improvisational Dance. She also trained in The Clairvoyant Program at Psychic Horizons Institute and The Colorado School of Transpersonal Counseling and Hypnotherapy where she became an internationally certified hypnotherapist. She completed her yoga teacher training in Rishikesh, India and has studied traditional dance in Bali, Thailand, Hawaii and Spain.Akasha is a best-selling contributing author of Activate Your Life and just finished contributing to a 2nd book on Awakening Experiences and their impact on daily life. She was the co-author of a Transformation from Trauma study which was published in the peer-reviewed academic journal, The International Journal of Transpersonal Psychology.When Akasha isn't helping people Become Counselors and Healers and Leading Retreats, she's Creating Lightcode Art, Writing Poetry or Traveling the World Solo studying Dance, Healing and Yoga. https://www.schoolofawakenedliving.com/

In this episode of Boom! Lawyered, Imani and Jess discuss a new school launched in Colorado that's designed to erase the separation of church and state in public education. They also explain why the conservative legal movement could finally succeed in getting taxpayers to fund religious schools.  Episodes like this take time, research, and a commitment to the truth. If Boom! Lawyered helps you understand what's at stake in our courts, chip in to keep our fearless legal analysis alive. Become a supporter today.Imani has relaunched her column, AngryBlackLady Chronicles. Sign up for our newsletters here to read it first, and listen to Imani's new podcast, B*tch, Listen, here. Going on a long roadtrip and want Imani and Jess to accompany you?

In this episode of Boom! Lawyered, Imani and Jess discuss a new school launched in Colorado that's designed to erase the separation of church and state in public education. They also explain why the conservative legal movement could finally succeed in getting taxpayers to fund religious schools.  Episodes like this take time, research, and a commitment to the truth. If Boom! Lawyered helps you understand what's at stake in our courts, chip in to keep our fearless legal analysis alive. Become a supporter today.Imani has relaunched her column, AngryBlackLady Chronicles. Sign up for our newsletters here to read it first, and listen to Imani's new podcast, B*tch, Listen, here. Going on a long roadtrip and want Imani and Jess to accompany you?

In 1984, three scientists dared to probe the mystery of life's origin by putting the prevailing theories of prebiotic and chemical evolution to the test. One of those men was engineer Walter Bradley. Today, Dr. Robert J. Marks joins host Andrew McDiarmid to share some of his personal anecdotes and professional insights about Dr. Bradley, a scientist, humanitarian, and trailblazer in the world of intelligent design who passed away this summer at the age of 81. A Distinguished Fellow of the Discovery Institute, Bradley taught mechanical engineering at Texas A&M University, Baylor University, and the Colorado School of Mines. His book, co-authored with chemist Charles Thaxton and geochemist Roger Olsen, deeply influenced prominent figures in the intelligent design research community like Stephen Meyer, Douglas Axe, and Jay Richards and helped to catalyze a new generation of inquiry into life's beginnings. The Mystery of Life's Origin was re-released in 2020 as a new, expanded second edition. Source

This week we step away from youth sports and talk about how parents can best support truly elite level, college, and professional level athletes on their journey in sports with Dr Sue Schimmel and Maureen Breeze, authors of the new book Playing the Long Game: A Handbook for Parenting Elite and College Athletes. We discuss conversation strategies, unintentional parental pressure, and investing in the relationship before you invest in the performance. Its a great conversation. Dr. Sue Schimmel is a clinical psychologist with over 20 years of experience working with professional and collegiate athletes. She serves as a registered provider for several major leagues, including the NHL, MLS, NFL, and PGA, and is also listed in the USOPC Mental Health Directory.  For three years, she worked intensively with a Division I men's soccer team and continues to consult with multiple collegiate programs. Dr. Schimmel is also the co-author of Playing the Long Game: A Handbook for Parenting Elite and College Athletes and co-founder of The CAP Project, which offers resources, consultation, and research to strengthen the coach–athlete–parent relationship.  Maureen Breeze is a leadership development specialist and certified executive coach serving organizations including NASA, Johns Manville, Arrow Electronics, Kraft Heinz, University of Colorado School of Medicine, and Newmont Mining, among others. She has facilitated leadership trainings and team capacity building sessions for organizations across the U.S. and in Germany, Mexico, Spain, Switzerland, and China. Maureen is the co-author of Playing the Long Game: A Handbook for Parenting Elite Athletes and cofounder of The CAP Project, which provides services and consultation to support the coach-athlete-parent dynamic. In addition, she is an adjunct professor at University of Denver's Center for Professional Development where she teaches business leaders coaching skills to support performance management and talent development.  Connect with the Authors: https://www.coachathleteparentproject.com/ BOOK A SPEAKER: Interested in having John or one of our speaking team come to your school, club or coaching event? We are booking November and December 2025 and Winter/Spring 2026 events, please email us to set up an introductory call John@ChangingTheGameProject.com PUT IN YOUR BULK BOOK ORDERS FOR OUR BESTSELLING BOOKS, AND JOIN 2025 CHAMPIONSHIP TEAMS FROM SYRACUSE MENS LAX, UNC AND NAVY WOMENS LAX, AND MCLAREN F1! These are just the most recent championship teams using THE CHAMPION TEAMMATE book with their athletes and support teams. Many of these coaches are also getting THE CHAMPION SPORTS PARENT so their team parents can be part of a successful culture. Schools and clubs are using EVERY MOMENT MATTERS for staff development and book clubs. Are you?  We have been fulfilling numerous bulk orders for some of the top high school and collegiate sports programs in the country, will your team be next? Click here to visit John's author page on Amazon Click here to visit Jerry's author page on Amazon Please email John@ChangingTheGameProject.com if you want discounted pricing on 10 or more books on any of our books. Thanks everyone. This week's podcast is brought to you by our friends at Sprocket Sports.  Sprocket Sports is a new software platform for youth sports clubs.  Yeah, there are a lot of these systems out there, but Sprocket provides the full enchilada. They give you all the cool front-end stuff to make your club look good– like websites and marketing tools – AND all the back-end transactions and services to run your business better so you can focus on what really matters – your players and your teams. Sprocket is built for those clubs looking to thrive, not just survive, in the competitive world of youth sports clubs.  So if you've been looking for a true business partner – not just another app – check them out today at https://sprocketsports.me/CTG. BECOME A PREMIUM MEMBER OF CHANGING THE GAME PROJECT TO SUPPORT THE PODCAST If you or your club/school is looking for all of our best content, from online courses to blog posts to interviews organized for coaches, parents and athletes, then become a premium member of Changing the Game Project today. For over a decade we have been creating materials to help change the game. and it has become a bit overwhelming to find old podcasts, blog posts and more. Now, we have organized it all for you, with areas for coaches, parents and even athletes to find materials to help compete better, and put some more play back in playing ball. Clubs please email John@ChangingTheGameProject.com for pricing.  Become a Podcast Champion! This weeks podcast is also sponsored by our Patreon Podcast Champions. Help Support the Podcast and get FREE access to our Premium Membership, with well over $1000 of courses and materials. If you love the podcast, we would love for you to become a Podcast Champion, (https://www.patreon.com/wayofchampions) for as little as a cup of coffee per month (OK, its a Venti Mocha), to help us up the ante and provide even better interviews, better sound, and an overall enhanced experience. Plus, as a $10 per month Podcast Super-Champion, you will be granted a Premium Changing the Game Project Membership, where you will have access to every course, interview and blog post we have created organized by topic from coaches to parents to athletes. Thank you for all your support these past eight years, and a special big thank you to all of you who become part of our inner circle, our patrons, who will enable us to take our podcast to the next level. https://www.patreon.com/wayofchampions

Today we were delighted to welcome Dr. Anas Alhajji, Managing Partner of Energy Outlook Advisors and Author of the Energy Outlook Advisors Substack (linked here). Dr. Alhajji is a leading expert on global energy markets. He advises governments, companies, financial institutions, and investors on oil and gas outlooks, energy geopolitics, energy security, and the impact of disruptive technologies on supply and demand. Anas previously served as Chief Economist at NGP Energy Capital Management and taught economics at the University of Oklahoma, the Colorado School of Mines, and Ohio Northern University. He holds an M.A. and Ph.D. in Economics, with a specialization in energy economics and policy. We were thrilled to hear his insights on the oil markets and beyond. In our conversation, Anas explains why mainstream oil-market commentary often falls short, how OPEC's role is to match supply and demand, and shares on-the-ground sentiment from ADIPEC including a focus on AI and “energy addition, not transition,” with OPEC's outlook seeing demand rising toward ~123 mmb/d. We discuss structural demand drivers including urbanization, immigration, rising incomes, and AI/data centers plus autonomous vehicles and the equity valuation puzzle amid inventories and spare capacity. Anas details the “oil on the water” debate including why recent headline numbers were overstated and how different factors from Iranian tankers suddenly broadcasting their transponders, Saudi barrels routed to Egypt but for Saudi-owned storage, Brazilian cargoes diverted to China, slower ship speeds, and others all swell oil-at-sea without adding supply. We explore how Aramco and ADNOC are evolving into global energy companies, why Saudi is leaning on renewables and nuclear to free oil for export, what to make of Saudi rigs and capacity, and why demand analysis should prioritize growth rates over absolute levels given definitional differences and the IEA's repeated upward revisions. Anas argues the IEA has persistently underestimated demand (including major multi-year revisions), contrasts IEA growth figures with stronger observed U.S. demand, and notes record U.S. crude without shale growth. We also touch on SPR strategy, why Anas believes the large 2022 release worked, his critique of “circular information” among agencies, banks, and media plus conformity shaping bearish narratives, the limited efficacy of current sanctions regimes, and much more. It was a wide-ranging discussion and we're grateful to Anas for sharing his expertise with us. To start the show, Mike Bradley noted that the U.S. Government shutdown has reached Day 35, tying the previous record set during President Trump's first term. In oil markets, WTI continues to hover around $60/bbl and is still being impacted by 2026 global oil supply concerns. OPEC+ agreed to raise December oil production by 137kbpd (consensus) but will pause oil production increments in January, February, and March. On the broader equity market front, the S&P 500 is down ~1% this week and looks to be losing some trading momentum after a huge recent run. Many of the Big6 AI/Tech stocks reported Q3 results last week, which were generally solid with AI capex spending budgets heading higher as expected. Over the last week or so, these same AI/Tech stocks were down 3-5% (on average) due to both growing valuation concerns and sustainability of this AI rally. These Big Tech stocks make up >35% of the S&P 500 market-cap, and if they sneeze, markets could catch a cold. Aramco reported quarterly results this week and struck a pretty constructive tone with one of its key highlights this quarter being an increase in their natural gas production capacity growth target (by 2030) to 80% up from 60%. On the E&P equity front, gassy E&Ps have been pretty constructive but aren't leaning into gas growth just yet, while oily E&Ps are taking a more cau

0:30 - Trump: You Must Vote for Cuomo 13:30 - JB's potty mouth 35:59 - Mark Levin at RJC on Tucker, et al 57:53 - Ben Shapiro on Tucker Carlson, Nick Fuentes...most important thing going on in America 01:13:38 - In Depth History w/ Frank From Arlington Heights 01:16:12 - Sports & Politics 01:33:29 - Mark Glennon, founder of Wirepoints, breaks down the recently passed Clean and Reliable Grid Affordability Act and the absurdities of Illinois’ green energy policy. For more from Mark substack.com/@markglennon 01:48:02 - Tom Williams, Associate Professor of Computer Science at the Colorado School of Mines and Human-Robot Interaction researcher, on how close we are to humanoid robots in the home and the opportunities if the current wave succeeds. For more on Tom’s work with robotics visit mirrorlab.mines.edu 02:06:45 - Why Dan Proft is SingleSee omnystudio.com/listener for privacy information.

Send us a textAbout Dr. Kaleb Abbott Abbott is an optometrist and assistant professor of ophthalmology at the University of Colorado School of Medicine. He is affiliated with both the Dry Eye Clinic and the Center for Ocular Inflammation, where he specializes in complex ocular surface diseases and participates in clinical trials and research related to these conditions. In addition to his clinical and research roles, he serves as vice-president for the Ocular Wellness and Nutrition Society, is Chair of the Nutrition, Disease Prevention, and Wellness Special Interest Group (SIG) for the American Academy of Optometry (AAO), and is a member of the advisory council for the Academic Medical Center Optometry AAO SIG. He also holds a position on the editorial advisory board for Modern Optometry and Optometry360 and is a graduate of the AAO Flom Leadership Academy. Furthermore, he hosts the Dry Eye and Ocular Surface Disease section of the Clinical Podcast Series through the American Academy of Optometry Foundation. In 2024, he was nominated for Colorado's Young Optometrist of the Year and recognized as a “One-to-Watch” by Modern Optometry.In 2019, Kaleb co-founded SunSnap Kids, a start-up that won first place in the inaugural Bright Ideas Pitch Competition in 2022 and third place in the Optometry Innovation Awards in 2023. He recently sold the majority of the company to focus more on his clinical and research responsibilities at the University of Colorado.When he's not seeing patients, conducting research, or working on SunSnap Kids, Dr. Abbott lectures on ocular surface diseases, writes articles, and serves as a medical reviewer for multiple journals, including The Ocular Surface and Optometry and Vision Science. He resides in Denver, CO, with his wife, daughter, and newborn twins.

Our mental health is impacted way before middle school. Jake speaks with Dr. Ayelet Talmi about the relevant influences within the first phase of life, how they impact the trajectory of a child's wellbeing, and what we should consequently pursue within public policy to improve outcomes for kids. Dr. Talmi is the Robert J. Harmon Distinguished Professor of Psychiatry and a Licensed Clinical Psychologist in the Departments of Psychiatry and Pediatrics at the University of Colorado School of Medicine and Children's Hospital Colorado, and she engages in integrated behavioral health and early childhood systems and workforce capacity building and implementation, direct service, scholarship, advocacy, and policy efforts in Colorado and nationally.

When we think of perimenopause, we hear about hot flashes—but what about the mood swings, anxiety, and depression no one talks about?In this episode, Sarah sits down with Reproductive Psychiatrist Dr. Lindsay Standeven to break down the mental health side of perimenopause. They talk about why women are more likely to face depression during this stage, what it means if you've struggled in pregnancy or postpartum, and—most importantly—what you can do now to protect your mental health.About Dr. Lindsay R. Standeven:Dr. Lindsay R. Standeven is a Clinical Associate Professor in the Department of Psychiatry at the University of Colorado School of Medicine and Adjunct Faculty at Johns Hopkins. After completing her residency training at Johns Hopkins Hospital, Dr. Standeven completed a two-year research and clinical fellowship specializing in reproductive psychiatry. Dr. Standeven spent the earlier part of her career on the faculty at Johns Hopkins, serving as the clinical and education director for the Johns Hopkins Reproductive Mental Health Center, where she oversaw clinical staff and taught psychiatry residents in reproductive psychiatry.She is passionate about teaching and advocacy in women's mental health and serves as a member of the National Curriculum in Reproductive Psychiatry, where she helped spearhead a training program in women's mental health for psychiatrists across the country. Her clinical expertise is in helping individuals struggling with mood-related changes due to pregnancy, postpartum, infertility, reproductive loss, Polycystic Ovary Syndrome, premenstrual syndrome, and perimenopause.

The childhood immunization schedule is one of the defining pillars of pediatric practice and remains among the most successful public health achievements of the modern era. Yet, in recent months, the schedule and the systems that support it have faced new challenges, raising serious concerns for pediatricians across the country. This episode was recorded live at the 2025 American Academy of Pediatrics National Conference in Denver, Colorado. In this episode, we discuss the latest AAP vaccine updates and the evolving landscape of childhood immunizations. Sue Kressly, MD, is a general pediatrician as well as the President of the AAP. Sean O'Leary, MD, is a pediatric infectious disease specialist at Children's Colorado and a professor at the University of Colorado School of Medicine. He is also chair of the AAP Committee on Infectious Diseases, otherwise known as the Red Book Committee. Some highlights from this episode include:  The latest AAP immunization guidance and policy updates  Changes currently impacting pediatricians  Insight into the near future of vaccine distributions  Strategies for combatting confusion and shifting vaccine confidence  For more information on Children's Colorado, visit: childrenscolorado.org. 

While asthma may be the most common chronic disease in pediatrics, it never feels routine for medical professionals. In the primary care setting, pediatricians carry the challenge and opportunity of turning this common condition into a well-managed part of daily life. In this episode, we'll dig into tools, strategies and insights that help us move from reactive treatment to proactive partnerships. The goal is for kids to focus less on their breathing and more on being kids. For this episode, we are joined by two asthma experts, Monica Federico, MD, and Heather De Keyser, MD. Dr. Federico is the Medical Director of the Asthma Program, as well as Population Health, at Children's Hospital Colorado. She is a Professor of Pediatrics at the University of Colorado School of Medicine. Dr. De Keyser is the Co-Director of the Multidisciplinary Asthma Clinic and an Assistant Professor of Pediatrics. Some highlights from this episode include:  Understanding the best options for treatment  Deciphering between asthma and other respiratory diagnoses  The latest updates in asthma guidelines  The importance of collaborating with schools on a child's action plan  Some resources mentioned in today's episode include guidelines for the management and diagnosis of asthma, as well as information from the Global Initiative for Asthma (GINA). For more information on Children's Colorado, visit: childrenscolorado.org. 

Constipation is one of the most common conditions that pediatricians see. From the toddler squirming on the exam table to the school-aged child with recurring belly pain, functional constipation is everywhere in pediatric primary care. In this episode, we will discuss how to diagnose, when additional testing is needed and treatment strategies that work.    Joining us for this episode is Christine Waasdorp-Hurtado, MD. She is a pediatric gastroenterologist, the Southern Colorado Executive Faculty Director for the Department of Pediatrics, and a professor at the University of Colorado School of Medicine.  Some highlights from this episode include:  Identifying the signs of functional constipation  Steps primary care physicians can take with families before referral  How advice changes depending on the child's age  Why managing constipation improves more than just a kid's bowel movements  For more information on Children's Colorado, visit: childrenscolorado.org. 

Imagine your body as a complex orchestra. Every hormone playing its part in harmony. When one section falls out of sync, the entire performance shifts. That's what happens with polycystic ovary syndrome (PCOS), especially in adolescents. During puberty, hormones are already in flux, and PCOS can add another layer of challenges.  Irregular periods, acne, excess hair growth, and weight gain are more than frustrating symptoms, they're signs of an underlying hormonal imbalance that deserves attention. For pediatricians, recognizing PCOS early can make all the difference in helping teens navigate both their physical health and emotional well-being.  In this episode, we sit down with Melanie Cree, MD, PhD, a pediatric endocrinologist at Children's Hospital Colorado, Director of the Multi-Disciplinary PCOS Clinic at the University of Colorado School of Medicine, and a professor.  Some highlights from this episode include:  Understanding why its name can be deceiving The role of the primary care provider in diagnosing and managing PCOS  Differences between abnormal and normal puberty changes  The impact of this lifelong disease  For more information on Children's Colorado, visit: childrenscolorado.org. 

Today, we're talking about the assassination of conservative activist Charlie Kirk; Nepal's government collapsing after Gen-Z protests; a shooting at a high school in Colorado; and other top news for Friday, September 12th. Stay informed while remaining focused on Christ with The Pour Over. Join over 1 million readers with our free newsletter here Looking to support us? You can choose to pay here Check out our sponsors! We actually use and enjoy every single one. Cru Surfshark Holy Post CCCU Upside HelloFresh Mosh LMNT Theology in the Raw Safe House Project Student Life Application Study Bible A Place For You Practicing Life Together Not Just Sunday Podcast

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

SUBSCRIBE TO JORDAN'S FREE NEWSLETTER. Get the facts, without the spin. UNBIASED offers a clear, impartial recap of US news, including politics, elections, legal news, and more. Hosted by lawyer Jordan Berman, each episode provides a recap of current political events plus breakdowns of complex concepts—like constitutional rights, recent Supreme Court rulings, and new legislation—in an easy-to-understand way. No personal opinions, just the facts you need to stay informed on the daily news that matters. If you miss how journalism used to be, you're in the right place. In today's episode: A Message From Me to You (0:00) What We Know About Charlie Kirk's Murder and the Shooter (6:17) What We Know About the Colorado School Shooting (16:34) What We Know About the Stabbing of Iryna Zarutska in Charlotte (19:37) House Committee Releases Trump's Alleged Letter to Epstein; Here's What It Says (27:46) Supreme Court Rules on ICE Stops; Here's What the Ruling Means (31:52) Rumor Has It: Was Trump an FBI Informant? Can Judges Really Be Judges Without a Law Degree? (40:35) GOOD NEWS (47:17) SUBSCRIBE TO JORDAN'S FREE NEWSLETTER. Watch this episode on YouTube. Follow Jordan on Instagram and TikTok. All sources for this episode can be found here.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

In our news wrap Thursday, authorities in Colorado say the 16-year-old who fired multiple shots at a high school was radicalized by an extremist network, the British ambassador to the U.S. was fired over his connections to convicted sex offender Jeffrey Epstein, more than 300 South Korean workers are heading home after a Georgia raid and Americans marked the 24th anniversary of the 9/11 attacks. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy